The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force ...
StockStory.org on MSN
A look back at biotechnology stocks’ Q4 earnings: Incyte (NASDAQ:INCY) vs. the rest of the pack
Looking back on biotechnology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Incyte ...
Biotech stocks have a way of making smart people do dumb things. It starts innocently enough. You read about a "breakthrough" that sounds like it came straight out of science fiction. A tiny company ...
The biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a ...
The biotech sector has found its footing again after several difficult years. The equal-weighted S&P Biotechnology ETF (XBI) has staged an impressive rebound, helped by a revival in risk appetite, ...
Shares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than ...
FBT selects 30 biotechnology stocks based on sales, sales as a percentage of R&D expenditures, and R&D growth compared to three years ago. The ETF launched 19 years ago and has delivered exceptional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results